Multiple sclerosis (MS) patients report improvements in their health-related quality of life following the use of medical cannabis preparations, according to observational data published in the journal Multiple Sclerosis and Related Disorders.
British researchers assessed the use of cannabis-based medicinal products (CBMPs) consisting of either flower or oil extracts in 141 MS patients enrolled in the UK Medical Cannabis Registry. (Since 2018, British specialists have been permitted to prescribe cannabis-based medicinal products to patients unresponsive to conventional medications.) Researchers assessed changes in patient-reported outcomes measures at one month, three months, and six months.
Patients reported sustained improvements in their physical and mental health following cannabis therapy. They reported few serious adverse health effects during treatment. Also, there was noted improvement in sleep, anxiety, and general HRQoL [health-related quality of life] measures over six months.
